The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.


Journal

Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 28 05 2021
revised: 21 12 2021
accepted: 04 01 2022
pubmed: 13 1 2022
medline: 26 3 2022
entrez: 12 1 2022
Statut: ppublish

Résumé

Leucine-rich repeat kinase 2 (LRRK2) has taken center stage in Parkinson's disease (PD) research as mutations cause familial PD and more common variants increase lifetime risk for disease. One unique feature in LRRK2 is the coexistence of GTPase/Roc (Ras of complex) and kinase catalytic functions, bridged by a COR (C-terminal Of Roc) platform for dimerization. Multiple PD mutations are located within the Roc/GTPase domain and concomitantly lead to defective GTPase activity and augmented kinase activity in cells, supporting a crosstalk between GTPase and kinase domains. In addition, biochemical and structural data highlight the importance of Roc as a molecular switch modulating LRRK2 monomer-to-dimer equilibrium and building the interface for interaction with binding partners. Here we review the effects of PD Roc mutations on LRRK2 function and discuss the importance of Roc as a hub for multiple molecular interactions relevant for the regulation of cytoskeletal dynamics and intracellular trafficking pathways. Among the well-characterized Roc interactors, we focused on the cytoskeletal-related kinase p21-activated kinase 6 (PAK6). We report the affinity between LRRK2-Roc and PAK6 measured by microscale thermophoresis (MST). We further show that PAK6 can modulate LRRK2-mediated phosphorylation of RAB substrates in the presence of LRRK2 wild-type (WT) or the PD G2019S kinase mutant but not when the PD Roc mutation R1441G is expressed. These findings support a mechanism whereby mutations in Roc might affect LRRK2 activity through impaired protein-protein interaction in the cell.

Identifiants

pubmed: 35016853
pii: S0006-8993(22)00005-1
doi: 10.1016/j.brainres.2022.147781
pii:
doi:

Substances chimiques

14-3-3 Proteins 0
LRRK2 protein, human EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
PAK6 protein, human EC 2.7.11.1
p21-Activated Kinases EC 2.7.11.1
GTP Phosphohydrolases EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

147781

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Susanna Cogo (S)

Department of Biology, University of Padova, Italy. Electronic address: s.cogo@reading.ac.uk.

Franz Y Ho (FY)

Department of Cell Biochemistry, University of Groningen, The Netherlands.

Elena Tosoni (E)

Department of Biology, University of Padova, Italy.

James E Tomkins (JE)

School of Pharmacy, University of Reading, UK.

Isabella Tessari (I)

Department of Biology, University of Padova, Italy.

Lucia Iannotta (L)

Department of Biology, University of Padova, Italy.

Thomas J Montine (TJ)

Department of Pathology, Stanford University School of Medicine, USA.

Claudia Manzoni (C)

Department of Pharmacology, University College London School of Pharmacy, UK.

Patrick A Lewis (PA)

Royal Veterinary College, London, UK; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

Luigi Bubacco (L)

Department of Biology, University of Padova, Italy; Centro Studi per la Neurodegenerazione CESNE, University of Padova, Italy.

Marie-Christine Chartier Harlin (MC)

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.

Jean-Marc Taymans (JM)

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.

Arjan Kortholt (A)

Department of Cell Biochemistry, University of Groningen, The Netherlands.

Jeremy Nichols (J)

Department of Pathology, Stanford University School of Medicine, USA.

Laura Cendron (L)

Department of Biology, University of Padova, Italy.

Laura Civiero (L)

Department of Biology, University of Padova, Italy; IRCCS San Camillo Hospital, Venice, Italy; Centro Studi per la Neurodegenerazione CESNE, University of Padova, Italy.

Elisa Greggio (E)

Department of Biology, University of Padova, Italy; Centro Studi per la Neurodegenerazione CESNE, University of Padova, Italy. Electronic address: elisa.greggio@unipd.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH